Awaiting development: Guidance and quality standards

Showing 191 to 200 of 332

Guidance and quality standards awaiting development
Title	Type
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]	Technology appraisal guidance
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance
Norucholic acid for treating primary sclerosing cholangitis [ID6583]	Technology appraisal guidance
Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia [ID6519]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [TSID11996]	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941	Technology appraisal guidance
Orforglipron for managing overweight and obesity [ID6516]	Technology appraisal guidance